147
Participants
Start Date
July 5, 2016
Primary Completion Date
October 2, 2023
Study Completion Date
October 2, 2023
Voxelotor
"* Part A: Voxelotor will be administered as oral capsules or tablets~* Part B: Voxelotor will be administered as oral capsules or tablets~* Part C: Voxelotor will be administered as oral dispersible tablets or powder for oral suspension~* Part D: Voxelotor will be administered as oral dispersible tablets or powder for oral suspension"
Children's Hospital of Pittsburgh of UPMC, Pittsburgh
The Children's Hospital of Philadelphia, Philadelphia
Children's National Medical Center, Washington D.C.
Brody School of Medicine at East Carolina University, Greenville
Children's Healthcare of Atlanta Scottish Rite, Atlanta
St. Jude Children's Research Hospital, Memphis
University Hospitals Cleveland Medical Center, Rainbow Babies & Children's Hospital, Cleveland
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
University of Illinois at Chicago Clinical Research Center, Chicago
Children's Mercy Hospital, Kansas City
Our Lady of the Lake Children's Hospital (IP Address), Baton Rouge
Brentwood Clinic UCSF Benioff Children's Hospital Oakland, Brentwood
Rutgers-Robert Wood Johnson Medical School, New Brunswick
American University of Beirut - Medical Center, Beirut
Rafik Hariri University Hospital, Beirut
Nini Hospital, Tripoli
University College London Hospital, NHS Foundation Trust, London
Barts Health NHS Trust, The Royal London Hospital, London
Guy's and St Thoma's NHS Foundation Trust, Evelina London Children's Hospital, London
Manchester University NHS Foundation Trust, Royal Manchester Children's Hospital, Manchester
Lead Sponsor
Pfizer
INDUSTRY